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Background: High recombinant protein productivity in mammalian cell lines is often associated with phenotypic
changes in protein content, energy metabolism, and cell growth, but the key determinants that regulate
productivity are still not clearly understood. The mammalian target of rapamycin (mTOR) signalling pathway has
emerged as a central regulator for many cellular processes including cell growth, apoptosis, metabolism, and
protein synthesis. This role of this pathway changes in response to diverse environmental cues and allows the
upstream proteins that respond directly to extracellular signals (such as nutrient availability, energy status, and
physical stresses) to communicate with downstream effectors which, in turn, regulate various essential cellular
processes.
Results: In this study, we have performed a transcriptomic analysis using a pathway-focused polymerase chain reaction
(PCR) array to compare the expression of 84 target genes related to the mTOR signalling in two recombinant CHO
cell lines with a 17.4-fold difference in specific monoclonal antibody productivity (qp). Eight differentially expressed
genes that exhibited more than a 1.5-fold change were identified. Pik3cd (encoding the Class 1A catalytic subunit of
phosphatidylinositol 3-kinase [PI3K]) was the most differentially expressed gene having a 71.3-fold higher level of
expression in the high producer cell line than in the low producer. The difference in the gene’s transcription levels was
confirmed at the protein level by examining expression of p110δ.
Conclusion: Expression of p110δ correlated with specific productivity (qp) across six different CHO cell lines, with a
range of expression levels from 3 to 51 pg/cell/day, suggesting that p110δ may be a key factor in regulating
productivity in recombinant cell lines.
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The production of biopharmaceutical products is one of
the fastest growing areas in the pharmaceutical industry
with sales of $99 billion in 2010 [1,2]. Many of these bio-
pharmaceutical products are used to treat critical diseases,
like hepatitis, cancer, heart disease, hemophilia, rheuma-
toid arthritis, and diabetes. Monoclonal antibodies (mAbs)
currently constitute more than 30% of total biopharma-
ceuticals and the portfolio of products is expected to grow
between 7-15% per annum in the coming years. Whilst
the future does looks bright for this sector, the emergence* Correspondence: m.al-rubeai@ucd.ie
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unless otherwise stated.of biosimilar competition is ensuring that manufacturers
of these products are continuously seeking methods of in-
creasing productivity of cell culture processes to maximise
yields.
Numerous attempts have been made to generate cell
lines that can produce large amounts of recombinant
products. Among the cell lines available for mAb pro-
duction are myeloma, hybridoma, and Chinese hamster
ovary (CHO) cell lines [3,4]. The use of CHO cells in
large-scale production is common [3,5-7] because of
their ability to express high recombinant protein levels
[8,9], grow to high cell densities [10-13], and to grow in
serum-free suspension culture [6,14-16]. CHO cells are
also suitable for use with expression systems, such astd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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tase (GS) [17-19].
High productivity is usually accompanied by slower
growth rates [20-25], and generating high-producing cell
lines with high growth rates should be advantageous to
further improve mAb production. However, maintaining
cell-specific productivity at high growth rates is chal-
lenging because both processes require high energy. Glu-
tamine and glucose are often consumed in the synthesis
of precursors for recombinant proteins rather than in
cell proliferation [26], which eventually leads to growth
repression.
The correlation between cell volume (size) and produc-
tivity has been clearly demonstrated [27] and is reflected
in the phenotypic changes in protein content and cell bio-
mass [13,28,29]. This increase in protein content may lead
to an increase in cell size [25,29,30]. The integration of
both protein synthesis and cell proliferation in response to
diverse environmental cues has been reported to be regu-
lated by a signalling pathway known as the mammalian
target of rapamycin (mTOR) signalling pathway [31,32].
As shown in Figure 1, upon receiving signals from
growth factors and hormones, mTOR is activated by
Akt/P13K signalling [33,34]. P13K catalyses the for-
mation of phosphoinositides-3-phosphate (PIP3) from
phosphoinositides-2-phosphate (PIP2), which then acti-
vates a protein kinase known as Akt [35]. The activated
mTOR initiates protein synthesis via two principal path-
ways; firstly through the inhibition of eukaryotic initia-
tion factor 4E binding protein (4EBP1) and secondlyFigure 1 The mTOR pathway signaling pathway. This pathway involves
to such extracellular signals as nutrient availability, energy status, and physithrough the activation of ribosomal protein S6 kinase
(S6K) [36,37]. These downstream effectors activate protein
synthesis by activating translation initiation and elonga-
tion factors, including eIF4E, eIF4B, S6, and eEF2 [32,38].
In addition to growth factors and hormones, mTOR
also receives signals from phosphatidic acid (PA) [39]
and amino acids [38,40,41]. In the presence of serum,
protein kinase C (PKC) is activated, and it sequentially
activates phospholipase D (PLD) which is responsible for
converting PA to phosphatidylcholine (PC) [39]. In con-
trast, the activation of mTOR by amino acids is unclear
[32]. It was reported to be regulated by the Ras protein
[41] and/or intracellular amino acids [38,42]. Moreover,
adenosine monophosphate kinase (AMPK) can also pre-
cisely modulate mTOR activity based on the adenosine
monophosphate (AMP) to adenosine triphosphate (ATP)
ratio [43]. In the presence of high intracellular ATP
levels, AMPK can be deactivated, leading to an increase
in protein synthesis [44,45].
A recent study highlighted the role of mTOR in im-
proving viability, cell growth, antibody production, and
robustness of the CHO cell line [46]. However, the
mechanism underlying these improvements has not yet
been elucidated. We believe that using a transcriptomic
approach, such as the pathway-focused polymerase chain
reaction (PCR) array, which has proven to be useful in a
similar study [47], we can elucidate the connections bet-
ween mTOR, cell growth, and productivity. Thus, this
study initially employed two recombinant CHO cell lines
with a 17.4-fold difference in specific productivity tocommunication between the upstream proteins that respond directly
cal stresses.
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mTOR signaling pathway. High productivity has been
associated partly with enhanced translation mechanisms
[48]. We therefore expected to see upregulation of genes
encoding mTOR upstream regulators such as, Akt
[49,50], PI3K [51,52], PLD [39,53], and Ras-related GTP
binding proteins (RagC) [41,54,55], as well as down-
stream effectors involved in translation mechanisms
such as S6 and S6K [56-59]. Since high gene expression
does not necessarily mean that the corresponding pro-
tein is also highly upregulated in the cell, we decided to
perform Western blot analysis to confirm that the se-
lected potential marker p110δ was expressed in increa-
sing amount in a panel of 6 CHO cell lines with varying
levels of productivity.
Methods
Cell lines and maintenance
This study employed a panel of six GS-CHO cell lines
(referred to as CL38, CL47, CL76, CL150, CL160 and
CL164) producing cB72.3 IgG4 monoclonal antibody with
varying levels of productivity. The cell lines were kindly
provided by Lonza Biologics (Slough, UK). The cell lines
were generated by transfection of the suspension-variant
derivatives CHO-K1 (CHOK1SV) with the glutamine syn-
thetase (GS) expression vector pcB72.3 containing light
chain (LC) and heavy chain (HC) cDNA, each driven by
the hCMV-MIE promoter [60,61]. Cells were maintained
in CD-CHO medium supplemented with 25 μM MSX.
Using three biological replicates, our experiments were
conducted in 125 ml shake flasks (SCHOTT Inc., Elmsford,
USA) at 37°C and 140 rpm agitation.
The six cell lines were numbered in descending order
according to their specific productivity, with [1] referring
to the most productive cell line and [6] referring to the
least productive cell line. These cell lines were thus re-
ferred to as CL47[1], CL76[2], CL150[3], CL164[4], CL38
[5] and CL160[6] throughout this study . Based on specific
productivity, CL47[1] was categorised as the high pro-
ducer; CL76[2], CL150[3], CL164 [4], and CL38[5], as
medium producers; and CL160[6], as the low producer.
Flow cytometric analysis of cell number and viability
Cell suspensions (490 μl) were removed from flasks and
placed in a flow cytometry tube and 10 μl propidium
iodide (PI) solution added from the stock solution
(0.5 μg/ml). Samples were mixed by gentle shaking and
analysed immediately for cell numbers and viability,
using Cell Lab Quanta SC flow cytometry (Beckman
Coulter Inc., CA, USA) equipped with an argon laser
(488 nm). Red fluorescence (PI) was collected using a
635 nm band pass filter. Analysis was undertaken by
loading an appropriate protocol for the acquired para-
meters: electronic volume (EV), log side scatter (SS), andPI integral; 10 000 observations were collected for
analysis. The evaluation of cell number was achieved by
gating areas in the EV versus log SS dot plot in which
living cells and dead cells appear.
We used the following equation to calculate the spe-
cific growth rate, μ:
μ ¼ lnXV 1−lnXV 0ð Þ
t1−t0
Where XV 1 and XV 0 symbolise the viable cell density
at time points t1 and t0, respectively.
Determination of antibody concentration
Enzyme-linked immunosorbent assay (ELISA) was used to
determine the concentration of mAb secreted by the cell
lines, as described previously [30]. The antibody was sand-
wiched between monoclonal anti-human IgG Fc (Sigma-
Aldrich, St. Louis, USA) and anti-human kappa light chain
horseradish peroxidase (HRP) conjugates (Sigma-Aldrich).
The concentration of antibody in the samples was deter-
mined using o-phenylenediamine (OPD; Sigma-Aldrich)
as a substrate, and the specific productivity, qp, was calcu-
lated using the following equation:
qp ¼
MAb½ 1− MAb½ 2
CVCT
where [MAb] represents the antibody concentration at a
particular time, while cumulative viable cell time
(CVCT) is the sum of the individual areas given by
CVCT ¼





Where x0 represents the cell number at the particular
time t0 and x1 represents the cell number at the elapsed
time t1.
Quantitative real-time PCR (qRT-PCR) analysis
3 × 106 cells were removed from the flask at the mid-
exponential phase (day three of the batch culture),
centrifuged, and washed twice by PBS. The sample was
treated with RNAlater and stored at −80°C until analysis,
at which point it was centrifuged to remove the RNAlater
stabilization reagent. RNA isolation was carried out using
the RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) ac-
cording to the manufacturer’s instructions. The concentra-
tion of RNA was determined using a NanoDrop ND-1000
UV–vis Spectrophotometer (Nanodrop Technologies,
Wilmington, DE, USA), and the integrity of RNA was
checked using an Agilent Bioanalyzer (Santa Clara, CA,
USA).
The expression levels of mTOR-related genes were quan-
tified using a mouse-mTOR-pathway-focused qRT-PCR
array from SA Biosciences (Frederick, Maryland, USA).
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plementary DNA (cDNA) was synthesized from the RNA
samples, using the RT2 First Strand Kit (SA Biosciences)
according to the manufacturer’s instructions. The cDNA
samples were mixed with RT2 SYBR Green/ROX qRT-
PCR Master Mix reagents (SA Biosciences) according to
the manufacturer’s instructions, and the qRT-PCR was
performed on these samples using ABI Prism 7500 FAST
sequence detection system (Applied Biosystems, Carlsbad,
CA, USA). The Ct values obtained from the qRT-PCR
analysis were normalised to five housekeeping genes (beta
glucuronidase [Gusb], hypoxanthine quinine phosphori-
bosyl transferase 1 [Hprt1], heat shock protein 90 alpha
[Hsp90ab1], glyceraldehyde-3-phosphate dehydrogenase
[Gapdh], and beta actin [Actb]). The normalization was
calculated by using the 2-ΔΔCT method, as previously des-
cribed [62].Total protein content
The total protein content was determined using the
QuantiPro BCA Assay Kit (Sigma-Aldrich). 3 × 106 cells
were removed from the flask, centrifuged and then
washed once with sterile-filtered PBS. The cells were
then centrifuged at 500 g for five minutes and super-
natant removed. A mixture of CelLytic M Cell Lysis
Reagent (Sigma-Aldrich) and a protease inhibitor cock-
tail (Sigma-Aldrich) was added to disrupt the cells. The
samples were mixed by vortexing for one minute, centri-
fuged at 15 000 g for 15 minutes at 4°C. The supernatant
was transferred to a new microcentrifuge tube and
stored at −20°C until analysis.Table 1 The culture characteristics and cell productivity
of high producer (CL47[1]) and low producer (160[6]) cell
lines during batch culture
47[1] 160[6]
CVCT (109 cell.hr/L) 244.48 ± 4.58 329.66 ± 17.99
Antibody concentration (μg/ml) 575.24 ± 137.55 52.08 ± 0.77
Growth rate (day-1) 0.63 ± 0.01 0.67 ± 0.01
qp (pg/cell/day;pcd) 50.54 ± 3.18 2.91 ± 1.45
The symbol “±” represents the standard deviation calculated between the
three biological replicates.Western blot analysis
For western blot analysis, 20 μg of total protein was mixed
in 2× Laemmli buffer (Sigma-Aldrich) and denatured at
95°C. The samples were then subjected to electropho-
resis on an 8% polyacrylamide gel (Thermo Scientific,
Waltham, MA, USA) using a Mini Protean 3 electropho-
resis system (Bio-Rad Laboratories, Waltham, MA, USA)
for 90 minutes. The proteins were transferred electro-
phoretically to a PVDF membrane (Millipore Corporation,
Cheshire, NH, USA) overnight. The membrane was
blocked in non-fat milk powder in PBST followed by an
overnight incubation with an anti-mouse p110δ PI3K anti-
body (Santa Cruz Biotechnology, Santa Crus, CA, USA).
The membrane was probed with a secondary antibody
solution containing anti-goat IgG peroxidase conjugates
prior to detection using a SuperSignal West Pico kit
(Thermo Scientific) according to the manufacturer’s
instructions. Upon reaction, the membrane was exposed,
developed, and fixed on a film. The band intensity was
measured by the AlphaDigiDoc RT2 gel documentation
system software (Alpha Innotech Corporation, CA, USA).Results
Comparing the growth and productivity of the high and
low producers
The C47 [1] and CL160 [6] lines, which expressed the re-
combinant chimeric IgG4 mAb, were grown in batch cul-
tures in three biological replicates. The cell numbers and
antibody concentrations, determined by flow cytometric
analysis and ELISA, respectively, were determined rou-
tinely throughout the culture duration until the cells
reached the death phase. The cell growth rates and cumu-
lative viable cell time (CVCT) were determined through-
out the exponential phase, from day one to day five of
batch culture as shown in Table 1. The viable cell density,
viability, and antibody concentration profiles are shown in
Figure 2. Following a normal growth curve, CL160[6] out-
performed CL47[1] in terms of growth, as demonstrated
by the calculated CVCT and growth rate (μ) of 329.66 ±
17.99 (109 cell.h/L) and 0.67 ± 0.01 (day-1) in CL160[6],
compared to 244.48 ± 4.58 (109 cell.h/L) and 0.63 ± 0.01
(day-1) in CL47[1], respectively. However, CL47 [1] sus-
tained high viability towards the decline phase (day 8),
while the viability of CL160[6], on the contrary, started to
decrease sharply on day seven. In CL 47[1], the specific
productivity and total antibody concentration, as indicated
in Table 1, were 17.4- and 11-fold higher than CL160[6],
respectively.
Differential mTOR-related gene expression between high
and low producers
We hypothesized that the differences in CL47 [1] and
CL160[6] productivity levels are a consequence of the
diverse mechanisms of cellular functions that are
controlled by mTOR. Using a commercially available
pathway-focused PCR array, the expression of 84 genes re-
lated to the mTOR signalling pathway were screened in
the template cDNA which was prepared from the samples
collected at the mid-exponential phase (day three of the
batch culture). Figure 3 demonstrates the relative expres-
sion of the mTOR-related genes exhibited by the high
producer (CL47[1], treated) in comparison to the low
producer (CL160[6], control). Student’s t-tests were con-
ducted to determine the significance of the gene expres-
sion changes. Out of the 84 mTOR-related genes in this
Figure 2 Viable cell density, viability, and antibody concentration profiles of high producer (CL47[1]) and low producer (CL160[6]) cells
lines during batch culture. Error bars symbolize the standard deviation as calculated between three biological replicates.
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(Pik3cd, Pik3cg, Pld1, Rragc, Ins2, Telo2, Rps6 and Prkab1),
with a corresponding statistical significance (P-value < 0.05)
between the high and low producers (Figure 4). These
genes were all upregulated.
Expression of genes in mTOR signalling pathway
The list of mTOR-related genes with significantly altered
expression in CL47[1] relative to CL160[6] is presented
in Table 2. Three differentially expressed genes involved
in insulin signalling were upregulated. The most upre-
gulated gene, pik3cdat 71.3-fold (P-value < 0.05), encodes
the catalytic subunit of the delta polypeptide p110δ. The
gene encoding a p110δ sibling, the gamma polypeptideFigure 3 The fold changes of mTOR-related gene expressions of GS-C
Values were calculated based on a relative quantification made between h
the 2-ΔΔCT method.(p110γ) subunit, was also significantly expressed but to a
lesser extent (6.6-fold; P-value < 0.05). The p110δ and
p110γ subunits are classified as Class 1A and 1B,
respectively and both receive signals from insulin and
various types of growth factors [51,63,64]. Another gene
related to insulin signalling that was also significantly
expressed was insulin 2 (Ins2), with a 3.06-fold change
(P-value < 0.05).
Ras-related GTP-binding protein C (Rragc) and phospho-
lipase D1 (Pld1) were also expressed significantly, with fold
changes of 3.08 and 4.63, respectively (P-value < 0.05).
Unlike RagC, which has a response specific to amino acid
availability [41,54,55], PLD1 is activated by mitogens such
as serum [39]. Moreover, the expression of the regulatoryHO cell lines at the mid-exponential phase of batch culture.
igh producer (CL47[1]) and low producer (160[6];control) lines by using
Figure 4 The log2 fold changes in gene expression between
high producer (CL47[1]) and low producer (160[6]) lines against
t-test P-values. Vertical line represents the threshold of fold changes
(i.e., 1.5); horizontal line represents the significant difference of t-test
P-values (i.e., 0.05). Significantly expressed genes (P-values < 0.05) are
tabulated in Table 2.
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served to be significantly differentially expressed (1.71-
fold, P-value < 0.05) though the expression was observed
to be minimal compared to other significant differential
mTOR-related genes. The activity of AMPK, precisely
controlled by the ratio of AMP to adenosine triphosphate
(ATP), reflects the cell energy status [43].
Among the genes that encode for downstream effectors
of mTOR, only ribosomal protein S6 (Rps6) was signifi-
cantly differentially expressed (1.89-fold, P-value < 0.05) in
CL47[1] relative to the CL160[6]. The interactions among
the upstream regulators, mTOR, and the downstream
effectors are indicated in Figure 1. Although mTOR was
not significantly expressed in this study, a gene that could
be linked to its presence, known as Telo2, was upregulated
by 2.44-fold (P-value < 0.05). This gene encodes telomereTable 2 The mTOR-related genes with at least a 1.5-fold chan
Gene symbol Description
Pik3cd Phosphatidylinositol 3-kinase catalytic delta
Pik3cg Phosphoinositide-3-kinase, catalytic, gamma
Pld1 Phospholipase D1
Rragc Ras-related GTP binding C
Ins2 Insulin II
Telo2 TEL2, telomere maintenance 2, homolog (S.
Rps6 Ribosomal protein S6
Prkab1 Protein kinase, AMP-activated, beta 1 non-camaintenance 2 (TEL2), which is responsible for mTOR
stabilisation and maturation [65,66]. However, the mecha-
nism by which TEL2 stabilizes mTOR remains poorly
understood [65,66].
The relationship among p110δ expression and specific
productivity, cell growth, and cell size
To investigate whether Pik3cd mRNA levels in the high
and low producers are predictive of p110δ expression,
western blot analysis was performed on samples harvested
from the mid-exponential phase (day three) of the batch
cultures. Figure 5a shows the expression of the p110δ
subunit in GS-CHO cell lines with different qp levels ran-
ging from 18 to 40 pg/cell/day. (CL47[1] = 50.54 pcd;
CL76[2] = 47.23 pcd; CL150[3] = 38.73 pcd; CL164[4] =
21.23 pcd; CL38[5] = 18.34 pcd and CL160[6] = 2.91 pcd).
The molecular characteristics of these cell lines have been
extensively studied previously [67]. The integrated density
values (IDV) corresponding to the band intensities were
measured. Pearson correlation coefficient analysis was
performed to determine the relationship between p110δ
subunit expression and the qp levels. The analysis revealed
that the expression of the p110δ subunit correlated with
the overall qp (ρ = 0.83, P-value < 0.05; Figure 5b). This
demonstrates the possibility that the p110δ subunit could
be a potential marker describing qp. Previous studies have
demonstrated that PI3K overexpression could influence
cell growth and proliferation [68-70]. Thus, we attempted
to correlate expression of the p110δ subunit with cell size
and CVCT. A Pearson correlation coefficient analysis in-
dicated that neither cell size nor CVCT (data not shown)
correlated with the expression of the p110δ subunit
(P-value > 0.05).
Discussion
Since Dreesen and Fussenegger [46] recently showed that
overexpression of mTOR in a CHO cell line significantly
improved recombinant antibody production, we decided
to investigate expression of members of the mTOR signal-
ling in a panel of CHO cell lines with different levels of
productivity. In order to address this question we used thege in expression level (P-values < 0.05)
Fold change P-value
polypeptide (+) 71.33 0.02




cerevisiae) (+) 2.44 0.01
(+) 1.89 0.05
talytic subunit (+) 1.71 0.02
Figure 5 Comparison of p110σ subunit expressions between (a) six GS-CHO cell lines with different productivity levels at the mid-exponential
phase of batch culture and (b) the correlation between p110σ expression and qp. Error bars symbolize the standard deviation as calculated
between three biological replicates.
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ability of the hamster array at that time. Given that the
mTOR signalling pathway is conserved from yeast to
mammals [71], we used mouse sequences instead of ham-
ster to quantify the levels of mTOR-related gene expres-
sions in this study. Previous transcriptomic studies which
relied on cross-hybridization to mouse DNA microarrays
have showed considerable success [72] and in general,
results from alignment to both mouse and rat reference
genomes suggest that CHO genomic sequences are gene-
rally more similar to mouse genomic sequences [73]. Of
the 84 mTOR-related genes present on the array only
eight genes including, Pik3cd, Pik3cg, Ins2, Pld1, Rragc,
Prkag3, Rps6 and Telo2 were identified as significantly
(p < 0.05) upregulated in CL47[1] in comparison to CL160
[6]. This panel of candidate genes could potentially deter-
mine high specific productivity in CHO cell lines. Two of
the genes that were highly expressed, Pik3cd and Pik3cg,
encode for p110δ and p110γ polypeptides, respectively
and are also present on the SA Biosciences hamster
mTOR signalling PCR array (PAJJ-098Z). These polypep-
tides differ at the regulatory subunit structure that isresponsible for mediating p110δ and p110γ recruitment
to the receptors of interest. The presence of p110δ as a
regulatory subunit facilitates the binding of p110γ to the
G protein beta subunit-like (Gβl) in response to a stimu-
lated G-protein couple receptor (GPCR). The recruitment
of the p110δ subunit to the activated receptor tyrosine
kinase (RTK) is, however, mediated by a different regula-
tory subunit, p85, in response to various extracellular
growth factors and insulin signals [35,74,75]. Hence, the
different receptors as targets imply that upregulation of
pik3cd gene could be independent of pik3cg (and vice
versa), even though these polypeptides share a common
role in catalysing phosphorylation of the inositol ring
at the D3 position of their downstream effectors, the
phosphoinositides.
Although the effects of p110δ in recombinant protein
production have yet to be clarified, its associations with
growth are better understood. The effects of p110δ over-
expression have been correlated to cell growth and cell
size in Drosophila, where expansion of the wing blade was
due to an increase in cell number and cell size. A reverse
effect on cell growth was observed in p110δ-deficient cells
Edros et al. BMC Biotechnology 2014, 14:15 Page 8 of 10
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between the CVCT and cell size with p110δ expression, is
not clear. The correlation could be weakened by the pre-
sence of the medium producer cell line in which other sig-
nalling pathways could have compensated for the lack of
effects of p110δ expression on cell growth. However, this
expression effect is more profound when only two ex-
tremes (high and low producers) were considered. CL160
[6] has a smaller cell size (data not shown) than CL47[1],
and this could partly result from the defective p110δ ex-
pression in CL160[6] [51,68]. There has been some studies
published which examined the use of genetic control of
the cell cycle to increase qp. However, these studies cannot
confirm that the production of recombinant protein is re-
lated to any specific phase of the cell cycle. However, the
increase in qp can be related to cell size rather than the
cell cycle phase [17]. This has been shown previously by
Bi et al. [30] in a cytostatic system utilising inducible ex-
pression of p21CIP1 to arrest CHO cells where a fourfold
increase of qp was obtained concomitant to a fourfold in-
crease in cell volume. Regardless of cell cycle phase, the
cell size could also be controlled by p110δ expression
through protein synthesis, a mechanism that is important
for cell growth and proliferation. As cells have to retain a
constant cell size during proliferation, a tight coordination
between cell growth and cell cycle progression is essential
for maintaining cell size and these processes are con-
trolled by p110δ expression as the upstream regulator of
mTOR signalling pathway [33,76,77].
While the regulation of p110δ activity is related to cell
growth, the activity of p110γ involves the regulation of
cell survival [78-80]. An increased resistance to cell
death was also observed as a result of the simultaneous
inhibition of p53 and activation of nuclear factor κB
(NF-κB) signalling pathways by Akt phosphorylation fol-
lowing the overexpression of the p110γ subunit in hu-
man cell lines [80].
In addition, Prkag3, Pld1, and Rragc genes were also
significantly expressed in CL47 [1], and these could be
related to high specific productivity. These genes encode
AMPK, PLD, and Ras-related GTP-binding protein C,
which represent upstream regulators of mTOR. The
altered expression of these genes may implicate the ex-
pression of the Rsp6 gene, which encodes the S6 protein.
The S6 protein regulates the translation of ribosomal
protein, elongation factor, and polyA-binding protein,
that could lead to ribosome biogenesis [81-83]. This sug-
gests that the improved specific productivity in CL47 [1]
could be due to the altered expression of the Rsp6 gene.
Our results were supported by a study conducted by
Bi et al. [30]. A significant increase in mAb titre was
shown to correlate with higher S6 protein expression in
an isopropyl-β-d-thiogalactoside (IPTG)-induced p21cip-
arrested CHO cell line [30].We also found altered expression of the Ins2 gene in
the CL47[1] cell line; this gene is not commonly ex-
pressed in non-pancreatic β cells. It is known that all
cells contain an insulin gene, but its expression can vary
in different cell types. The expression of Ins2 could be
controlled at the transcriptional level. It was shown pre-
viously by Kuroda et al. [84] that the Ins2 gene was fully
methylated and becomes demethylated as the cells dif-
ferentiate into insulin-expressing cells in vitro [84]. If
CHO cells could produce insulin, this would make the
cells less dependent on exogenous insulin, which is
certainly an advantageous trait in recombinant protein
production.
Conclusion
This study provides a better understanding of the role of
the mTOR signalling pathway in GS-CHO cell lines and
identifies the importance of this pathway in recombinant
protein production. We also highlight the presence of
the p110δ subunit of PI3K as a potential key regulator in
productivity that may represent a future target for cell-
engineering strategies for enhancing productivity. Cell-
engineering approaches such as overexpression and/or
gene silencing could be used to verify the roles of p110δ
and p110γ in cellular functions that may be involved in
recombinant protein production.
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